Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Blood

• Publication date

  2012-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2012-03-415307PMID 22896000PMCID PMC4916583
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

  2011cited by this paper
• Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

  2011cited by this paper
• Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.

  2011cited by this paper
• Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.

  2011cited by this paper
• The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

  2011cited by this paper
• Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

  2010cited by this paper
• The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.

  2010cited by this paper
• Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR‐ABL kinase domain mutation T315I

  2010cited by this paper
• Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

  2010cited by this paper
• Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  2010cited by this paper
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

  2010cited by this paper
• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  2009cited by this paper
• Inhibitory Effects of Omacetaxine on Leukemic Stem Cells and BCR-ABL-Induced Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Mice

  2009cited by this paper
• Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.

  2009cited by this paper
• Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

  2009cited by this paper
• Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin

  2008cited by this paper
• Kinase domain point mutations in Philadelphia chromosome‐positive acute lymphoblastic leukemia emerge after therapy with BCR‐ABL kinase inhibitors

  2008cited by this paper
• BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

  2007cited by this paper
• Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.

  2007cited by this paper
• ABT‐737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug‐resistance mechanisms

  2007cited by this paper
• Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

  2007cited by this paper
• Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

  2005cited by this paper
• Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.

  2004cited by this paper
• Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

  2003cited by this paper
• Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia.

  1999cited by this paper
• Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase.

  1995cited by this paper

• Discovery of novel and potent harringtonine derivative P2 via systematic structure-activity Optimization: Semi-Synthesis, anti-leukemia activity, and mechanism study.

  2025cites this paper
• Homoharringtonine: mechanisms, clinical applications and research progress

  2025cites this paper
• Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

  2025cites this paper
• Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications

  2024cites this paper
• Novel targeted therapies in chronic myeloid leukemia

  2024cites this paper
• Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy

  2024cites this paper
• SMYD5 is a ribosomal methyltransferase that catalyzes RPL40 lysine methylation to enhance translation output and promote hepatocellular carcinoma

  2024cites this paper
• Exploring treatment decision-making in chronic myeloid leukemia in chronic phase

  2024cites this paper
• Treatment of T315I mutation: Indian perspective

  2024cites this paper
• Homoharringtonine in the treatment of acute myeloid leukemia: A review

  2024cites this paper
• Analysis of Clinical Trials Using Anti-Tumor Traditional Chinese Medicine Monomers

  2024cites this paper
• Sorafenib combination with imatinib enhances apoptotic and cell cycle arrest effects with no effect on viability and BCR-ABL expression of K-562 cells

  2024cites this paper
• Management of chronic myeloid leukemia in 2023 – common ground and common sense

  2023cites this paper
• Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review

  2023influential citation
• Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms

  2023cites this paper
• Potential Antiviral Action of Alkaloids

  2022cites this paper
• The Metabolic Signature of AML Cells Treated With Homoharringtonine

  2022cites this paper
• Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities

  2022cites this paper
• Developing therapeutic approaches for chronic myeloid leukemia: a review

  2022cites this paper
• Development and characterization of anti-fibrotic natural compound similars with improved effectivity

  2022cites this paper
• Third-line therapy for chronic myeloid leukemia: current status and future directions

  2021cites this paper
• Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance

  2021cites this paper
• Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma

  2021influential citation
• Targeting the Human 80S Ribosome in Cancer: From Structure to Function and Drug Design for Innovative Adjuvant Therapeutic Strategies

  2020cites this paper
• Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy

  2020cites this paper
• Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Cancer Chemoprevention by Natural Plant Products and Their Derivatives: Clinical Trials

  2020cites this paper
• Transcription and Translation Inhibitors in Cancer Treatment

  2020cites this paper
• Pharmacotherapeutic Botanicals for Cancer Chemoprevention

  2020cites this paper
• Regiodivergent synthesis of aza-quaternary carbon derivatives from pyrazolinone ketimines and 1,2-dihydroquinolines

  2020cites this paper
• Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX

  2019cites this paper
• New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia

  2019cites this paper
• Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.

  2019cites this paper
• Early Predictors of Suboptimal Response to CML Therapy Could Help in Determining Treatment Strategy

  2018cites this paper
• A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected

  2018cites this paper
• Chronic Myeloid Leukemia , Version 1 . 2019 Clinical Practice Guidelines in Oncology

  2018cites this paper
• Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

  2018cites this paper
• Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products

  2018cites this paper
• Neurological complications of new chemotherapy agents.

  2018cites this paper
• Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia.

  2018cites this paper
• A phase II study of omacetaxine mepesuccinate for patients with higher‐risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents

  2018cites this paper
• Neurological Complications of Chemotherapy

  2018cites this paper
• Chronic Myeloid Leukemia (CML)

  2018cites this paper
• Diagnosis and Treatment of Chronic Myeloid Leukemia

  2018cites this paper
• Diagnosis and Treatment of Chronic Myeloid Leukemia ( CML ) in 2015

  2017cites this paper
• Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia

  2017cites this paper
• Chemistry, Bioactivity, and the Structure-Activity Relationship of Cephalotaxine-Type Alkaloids From Cephalotaxus sp.

  2017cites this paper
• Novel homobarringtonie-containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy.

  2017influential citation
• Bosutinib as a fourth-line therapy for a patient with T315I-positive lymphoid blastic phase chronic myeloid leukemia: A case report

  2017cites this paper
• Current Management Approaches of Chronic Myeloid Leukemia

  2017cites this paper
• Clinical features and outcomes in chronic myeloid leukemia with T 315 I mutation

  2017cites this paper
• Homoharringtonine binds to and increases myosin‐9 in myeloid leukaemia

  2016cites this paper
• 伴T315I突变的Ph+急性淋巴细胞白血病和慢性髓性白血病的特征及疗效比较

  2016cites this paper
• Anticancer Alkaloids from Trees: Development into Drugs

  2016cites this paper
• Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia

  2016cites this paper
• The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia

  2016cites this paper
• The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

  2016cites this paper
• A novel platform for creating digital PCR assays to detect genetic translocations and its application to the initial diagnosis of cancer.

  2016cites this paper
• Protein synthesis inhibitors of natural origin for CML therapy: semisynthetic homoharringtonine (Omacetaxine mepesuccinate).

  2016cites this paper
• Off-Target Effects of BCR-ABL and JAK2 Inhibitors

  2016cites this paper
• Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia

  2016cites this paper
• The Role of New TKIs and Combinations with Interferon-α for the Treatment of CML

  2016cites this paper
• Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia

  2016cites this paper
• A safety evaluation of omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia

  2016influential citation
• Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

  2016cites this paper
• Treatment of chronic myelogenous leukemia.

  2016cites this paper
• The role of stem cell transplantation for chronic myelogenous leukemia in the 21st century.

  2015cites this paper
• Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate

  2015influential citation
• Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.

  2015cites this paper
• Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?

  2015cites this paper
• BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report

  2015cites this paper
• ENDEMIC PLANTS FROM MAURITIUS ISLANDS AS POTENTIAL ANTICANCER BIORESOURCES

  2015cites this paper
• A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy

  2015cites this paper
• Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

  2015cites this paper
• Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis

  2015cites this paper
• Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment

  2015cites this paper
• Small-molecule induction of phospho-eIF4E sumoylation and degradation via targeting its phosphorylated serine 209 residue

  2015cites this paper
• Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

  2015cites this paper
• An Overview and Update of Chronic Myeloid Leukemia for Primary Care Physicians

  2015cites this paper
• Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance

  2015cites this paper
• Update on emerging treatments for chronic myeloid leukemia

  2015cites this paper
• How we will treat chronic myeloid leukemia in 2016.

  2015influential citation
• Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation: Kinase Inhibitors

  2015cites this paper
• [State-of-the-art management of CML in 2015 and future prospects].

  2015cites this paper
• Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia

  2014cites this paper
• A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

  2014cites this paper
• BCR-ABL Point Mutations and TKI Treatment in CML Patients

  2014cites this paper
• Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations

  2014cites this paper
• Omacetaxine: A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia

  2014cites this paper
• Homoharringtonine and omacetaxine for myeloid hematological malignancies

  2014cites this paper
• CCR Drug Updates Omacetaxine : A Protein Translation Inhibitor for Treatment of Chronic Myelogenous Leukemia

  2014cites this paper
• Chronic Myeloid Leukemia— What Else is there Beyond Protein Kinase Inhibitors?

  2014cites this paper
• Omacetaxine mepesuccinate in chronic myeloid leukemia

  2014cites this paper
• Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?

  2014cites this paper
• Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives.

  2014cites this paper
• Targeting tumour-supportive cellular machineries in anticancer drug development

  2014cites this paper
• Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.

  2014cites this paper
• Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.

  2014cites this paper
• Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations

  2014cites this paper